149 related articles for article (PubMed ID: 7651460)
1. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
Montastruc JL; Fabre N; Blin O; Senard JM; Rascol O; Rascol A
Mov Disord; 1995 May; 10(3):355-7. PubMed ID: 7651460
[No Abstract] [Full Text] [Related]
2. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
Montastruc JL; Fabre N; Rascol O; Senard JM; Blin O
Mov Disord; 1994 Mar; 9(2):242-3. PubMed ID: 8196695
[No Abstract] [Full Text] [Related]
3. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
4. Clozapine withdrawal symptoms in a Parkinson's disease patient.
Zesiewicz TA; Borra S; Hauser RA
Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
[TBL] [Abstract][Full Text] [Related]
5. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
[No Abstract] [Full Text] [Related]
6. Protective effect of selegiline in the early and late phases of Parkinson's disease.
Csanda E; Tárczy M
Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
[No Abstract] [Full Text] [Related]
7. Combination therapy of parkinsonism with deprenyl.
Behari M; Ahuja GK; Singh K; Prasad K
J Assoc Physicians India; 1992 Jun; 40(6):365-7. PubMed ID: 1452557
[TBL] [Abstract][Full Text] [Related]
8. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Schindehütte J; Trenkwalder C
Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
[TBL] [Abstract][Full Text] [Related]
9. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
Factor SA
Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
[No Abstract] [Full Text] [Related]
10. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
11. Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease.
Nakashima K; Shimoda M; Kuno N; Takahashi K
Mov Disord; 1994 Jan; 9(1):106-7. PubMed ID: 8139589
[No Abstract] [Full Text] [Related]
12. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
13. The clinical features of Parkinson's disease in 100 histologically proven cases.
Hughes AJ; Daniel SE; Lees AJ
Adv Neurol; 1993; 60():595-9. PubMed ID: 8420197
[No Abstract] [Full Text] [Related]
14. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
[TBL] [Abstract][Full Text] [Related]
15. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
[No Abstract] [Full Text] [Related]
17. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
18. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
[TBL] [Abstract][Full Text] [Related]
19. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
20. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
